Symphogen
Randi Westh began their work experience in 2010 as a PHD Student at the University of Copenhagen. During this time, they took two periods of parental leave. Randi completed their PHD in May 2015. From 2016 to 2018, Randi worked at the University of Copenhagen as a Coordinator and Fundraiser, as well as a Postdoctoral Researcher. Since 2018, they have been working as a Scientist at Symphogen.
Randi Westh completed their Msc. in Nanoscience at Københavns Universitet - University of Copenhagen in 2010. Randi went on to pursue a Doctor of Philosophy (Ph.D.) in Neuroscience at the same university, completing their studies in 2015.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.